Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign for AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets), the first and only treatment specifically approved by the U.S. Food and Drug Administration (FDA) for adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy. The integrated campaign encourages healthcare professionals (HCPs) and patients to rethink what may be possible at and beyond the earliest recurrence for people living with KRAS-mutated recurrent LGSOC.